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ABSTRACT
Objectives: Clinical trial data indicate that posaconazole is superior to
ﬂuconazole (FLU) or itraconazole (ITRA) in preventing invasive fungal
infections (IFIs) among neutropenic patients. Our objective was to assess
the cost-effectiveness of posaconazole versus FLU or ITRA for prevention
of IFIs among neutropenic patients.
Methods: We used modeling techniques to assess the cost-effectiveness of
posaconazole versus FLU or ITRA in the prevention of IFIs among patients
with acute myelogenous leukemia (AML) or myelodysplastic syndromes
(MDS) and chemotherapy-induced neutropenia. The probabilities of expe-
riencing an IFI, IFI-related death, and death from other causes over 100
days of follow-up were estimated from clinical trial data. Long-term
mortality, drug costs, and IFI treatment costs were obtained from second-
ary sources.
Results: Posaconazole is associated with fewer IFIs per patient (0.05 vs.
0.11) relative to FLU or ITRA over 100 days of follow-up, and lower
discounted costs ($3900 vs. $4500) and increased life-years (2.50 vs. 2.43
discounted) over a lifetime horizon. Results from a probabilistic sensitivity
analysis indicate that there is a 73% probability that posaconazole is cost
saving versus FLU or ITRA and a 96% probability that the incremental
cost-effectiveness ratio for posaconazole is at or below $50,000 per life-
year saved.
Conclusions: We conclude that posaconazole is very likely to be a cost-
effective alternative to FLU or ITRA in the prevention of IFIs among
neutropenic patients with AML and MDS, and may result in cost savings.
Keywords: cost-effectiveness, decision analysis, invasive fungal infection,
prophylaxis.
Introduction
The incidence of invasive fungal infections (IFIs) such as candidi-
asis, aspergillosis, and cryptococcosis has risen dramatically over
the last 20 years, largely due to factors such as improvements in
the supportive care of immunocompromised patients, increases
in the number and complexity of solid organ and hematopoietic
cell transplants performed, and increased use of antibiotics [1].
Persons at high risk for IFIs include those receiving cytotoxic
chemotherapy for the treatment of cancer, transplant recipients,
and patients with HIV/AIDS. These infections are associated
with signiﬁcant morbidity and mortality, with fatality rates for
aspergillosis as high as 60% [2]. In addition, health-care costs
for the treatment of IFIs are signiﬁcant, with estimates for
aspergillosis ranging from $46,400 for cancer/neoplasia patients
to $83,900 for transplant recipients [3]. A number of studies
have documented the importance of early diagnosis of IFI [4–6].
One study reported that when treatment for IFI was initiated
within 10 days of onset, the mortality rate was 41%, versus 90%
mortality when treatment was initiated more than 10 days past
onset [6]. Nevertheless, early diagnosis is challenging because of
difﬁculties in performing invasive diagnostic tests on seriously ill
patients [4]. Given the challenges of diagnosis and the negative
outcomes associated with delays in diagnosis, prophylaxis with
an antifungal agent is now recommended for patients at high risk
for IFIs [7].
Posaconazole (Noxaﬁl, Schering-Plough Corp., Kenilworth,
NJ) is a new broad-spectrum antifungal agent that has been
shown to be efﬁcacious in treating various fungal pathogens that
are resistant to currently available therapy, including molds and
yeasts such as candida [8,9]. Results from a recently published
multinational randomized controlled trial indicate that posa-
conazole is superior to ﬂuconazole (FLU) or itraconazole (ITRA)
in preventing IFIs among patients with acute myelogenous leu-
kemia (AML) or myelodysplastic syndromes (MDS) who are
neutropenic following chemotherapy [10]. Posaconazole was
also associated with a lower incidence of aspergillosis speciﬁcally
and lower rates of IFI-related death and all-cause mortality [10].
Based on evidence from clinical trials, the National Comprehen-
sive Cancer Network (NCCN) recently recommended that neu-
tropenic patients with AML or MDS receive prophylaxis with a
mold-active antifungal, such as posaconazole [7].
While posaconazole has been proven to reduce the incidence
of IFIs relative to FLU or ITRA among neutropenic patients with
AML and MDS, it is unknown whether the added cost of the
drug relative to other azoles on the market is worth the beneﬁts
of prophylaxis. Accordingly, we conducted a cost-effectiveness
analysis of posaconazole versus FLU or ITRA for the prevention
of IFIs among high-risk neutropenic AML and MDS patients in
the United States.
Methods
Overview
We employed techniques of decision analysis to construct and
estimate a model of the prevention of IFIs among patients at high
risk due to chemotherapy-induced neutropenia. Patients in the
model are assumed to receive either posaconazole or standard
therapy (i.e., FLU or ITRA) for the prevention of IFIs. Based on
prophylaxis received, the model predicts the likelihoods of IFI
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and death. Measures of effectiveness included IFIs avoided and
life-years saved; these were used along with estimates of total
costs (in 2006 US dollars) to calculate the incremental cost per
IFI avoided and incremental cost per life-year saved of posacona-
zole versus FLU or ITRA from a payer perspective.
The model was estimated using data from a randomized,
open-label, evaluator-blinded multicenter trial in which patients
received either posaconazole (N = 304) or FLU (N = 240) or
ITRA (N = 58) (the decision to give FLU or ITRA was made at
the investigators’ discretion based on local treatment patterns)
for a maximum of 84 days [10]. Prophylaxis was given with each
cycle of chemotherapy until recovery from neutropenia and
complete remission, occurrence of an IFI, or for up to 12 weeks
following randomization, whichever came ﬁrst. Patients were
followed for a total of 100 days following randomization. We
modeled clinical events during the ﬁrst 100 days with chance
nodes reﬂecting the probabilities of IFI, IFI-related death, and
other death; survival beyond 100 days was modeled by extending
the decision tree with 1-month Markov cycles that run until all
patients have died.
The structure of the model is illustrated in Figure 1. Patients at
risk of IFI enter the decision tree and receive prophylaxis with
either posaconazole or FLU or ITRA. Patients who experience an
IFI are subsequently at risk of death from IFI. Patients who do
not have an IFI, as well as those who survive an IFI, are at risk of
short-term (i.e., within 100 days) death from causes unrelated to
IFI. Patients who survive the 100-day period following initiation
of prophylaxis enter aMarkov subtree in which their monthly risk
of death is speciﬁc to the underlying condition (i.e., AMLorMDS)
but independent of whether or not they previously had an IFI.
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Figure 1 Decision-tree model of posaconazole versus ﬂuconazole or itraconazole for the prevention of invasive fungal infections (IFIs) among a high-risk
neutropenic population in the United States.
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Model Parameters and Data Sources
Table 1 contains the model parameters and data sources, which
are described in more detail below.
Efﬁcacy of prophylaxis. Data on the probabilities of IFI on
posaconazole and FLU or ITRA were estimated based on 100-
day follow-up data from the multinational clinical trial [10].
Survival following prophylaxis. Results from the clinical trial
indicate that relative to prophylaxis with FLU or ITRA, prophy-
laxis with posaconazole is associated with lower rates of IFI-
related death and death from any cause. Nevertheless, our model
requires probability estimates for IFI-related death conditional
on experiencing an IFI, as well as for non-IFI death. We used trial
data to calculate these probabilities during the 100-day period
following initiation of prophylaxis [10]. As the observed case
fatality rates for IFI were not markedly or signiﬁcantly different
between treatment arms, case fatality rates were pooled, and the
probability of IFI-related death conditional upon experiencing an
IFI was assumed to be equal for both treatment groups.
While in the trial, there were fewer all-cause and IFI-related
deaths among posaconazole patients relative to FLU or ITRA
patients, observed rates of non-IFI death were not different
between treatment groups. We therefore pooled the rates of
non-IFI death from the trial and assumed that the risk of non-
IFI-related death is independent of treatment group.
Survival beyond 100 days. The model was extrapolated beyond
the trial period by applying rates of relative survival for patients
with AML and MDS to those who survived the 100-day trial
period. The age-adjusted, 5-year relative survival rate for patients
with AML was obtained from published data from the National
Cancer Institute’s Surveillance, Epidemiology, and End Results
(SEER) registry [11]. The 5-year relative survival rate for MDS
patients was obtained from a long-term follow-up study of inten-
sive chemotherapy regimens among patients with MDS [12].
Relative survival rates were weighted by the proportions of
patients assumed to have AML and MDS in the model, and the
weighted estimate was applied to age-speciﬁc death rates for
the general population obtained from US Life Tables [13].
IFI treatment costs. The cost of treating an IFI in a US hospital
was estimated using data from the 2004 Healthcare Cost and
Utilization Project-Nationwide Inpatient Sample (unpublished
data from analysis of HCUP-NIS, Schering-Plough Corp., 2007).
Inpatient charges were estimated for patients with blood cancers
who experienced an IFI as well as for a matched cohort who did
not experience an IFI, where the matching was based on age, sex,
hospital region, hospital teaching status, and high-risk conditions
(i.e., cancer, HIV, chronic obstructive pulmonary disease, diabe-
tes, and solid organ, hematopoietic stem cell, or bone marrow
transplant). Among patients with an IFI, candidiasis (40%),
other mycoses (including allescheriosis and other unspeciﬁed
mycoses) (36%), aspergillosis (16%), and cryptococcosis (9%)
were the most common types of infection. Charges were con-
verted to costs using hospital-speciﬁc cost-to-charge ratios, and
the difference in total costs between IFI cases and controls was
assumed to represent the excess cost attributable to the IFI. The
attributable cost was updated to 2006 US dollars using the
Medical Care Services component of the Consumer Price Index
from the Bureau of Labor Statistics.
Costs of antifungal prophylaxis. Acquisition costs for FLU and
ITRA were estimated using data from the Analysource database
(data on ﬁle, Schering-Plough Corp., 2006). The cost of posa-
conazole was obtained from Schering-Plough Corp. Consistent
with the formulations and dosages given in the trial, the daily
costs of the agents were based on oral suspension formulations as
follows: 400 mg generic FLU once daily, 200 mg generic ITRA
twice daily, and posaconazole 600 mg daily. Total drug costs
were estimated based on the average duration of prophylaxis in
each arm of the trial and, for the FLU or ITRA arm, weighted by
the proportions receiving each drug.
Analyses
Target patient population. Patients entering the model were
assumed to have similar demographic and clinical characteristics
Table 1 Model parameters and data sources
Model parameter Estimate Data source
Efﬁcacy of prophylaxis
Probability of IFI with ﬂuconazole or itraconazole 0.11 [10]
Probability of IFI with posaconazole 0.05 [10]
Survival following prophylaxis
Probability of IFI-related death, given IFI
Posaconazole 0.43 [10]
Fluconazole or itraconazole 0.43 [10]
Probability of other death within 100 days
Posaconazole 0.16 [10]
Fluconazole or itraconazole 0.16 [10]
5-year relative survival for AML 0.21 [11]
5-year relative survival for MDS 0.08 [12]
Costs (2006$)
IFI treatment costs $40,583 Unpublished data from HCUP-NIS analysis, Schering-Plough Corp., 2007
Drug costs (per day)
Posaconazole $72 Data from Schering Plough Corp.
Fluconazole $2.74 Analysource database, data on ﬁle, Schering-Plough Corp., 2006
Itraconazole $1.57 Analysource database, data on ﬁle, Schering-Plough Corp., 2006
Mean duration of prophylaxis (days)
Fluconazole 28.9 [10]
Posaconazole 24.9 [10]
Itraconazole 24.9 [10]
Discount rate 3% [17]
AML, acute myelogenous leukemia; IFI, invasive fungal infection; MDS, myelodysplastic syndromes.
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to patients in the trial—that is, approximately 50% men and
50% women, average age of 50 years, 86% with AML and 14%
with MDS who are at high risk for IFI due to chemotherapy-
induced neutropenia. Consistent with the distributions in the
trial, it was assumed that 81% of patients in the FLU or ITRA
group receive FLU and 19% receive ITRA.
Base-case analyses. In base-case analyses, cumulative numbers
of IFIs over a 100-day period and life-years and expected costs
over a lifetime horizon were estimated for the posaconazole and
FLU or ITRA strategies. These were used to estimate the incre-
mental costs per IFI avoided and per life-year saved, respectively,
with posaconazole versus FLU or ITRA from a payer perspective.
Total costs included those for prophylaxis and inpatient treat-
ment of IFIs among those who developed them. Based on the
premise that most cancer costs are concentrated around the time
of diagnosis and death [14,15], differences in the costs of treating
the underlying condition between groups were assumed to be
small and thereby excluded from the base-case analysis. Other
costs, such as patient time and travel costs, were omitted because
they are negligible relative to treatment costs. All costs and health
outcomes were discounted at 3% per year.
Alternative scenario. In the base-case analysis, we assumed that
IFI-related death is independent of prophylaxis received (i.e., risk
of death from IFI is the same for both prophylaxis groups); in an
alternative scenario, we used the observed, treatment-speciﬁc IFI
case fatality rates from the trial.
Sensitivity analyses. Multiple one-way sensitivity analyses were
conducted to test the robustness of model results to changes in
key parameters, particularly drug efﬁcacy, costs, and long-term
survival. For the efﬁcacy of posaconazole, the range used in the
one-way sensitivity analysis was calculated using the 95% con-
ﬁdence interval on the difference in risk between the posacona-
zole and FLU or ITRA arms from the clinical trial. For the mean
number of days on prophylaxis, the range was estimated using
the SD of the mean exposure days from the trial. The range for
the cost to treat an IFI was calculated using the standard error
on the incremental cost between IFI cases and controls from the
HCUP database analysis. The efﬁcacy of FLU or ITRA and the
5-year relative survival rate with AML were varied from 75% to
125% of their base-case values.
A second-order probabilistic Monte Carlo sensitivity analysis
[16] was conducted to assess the effects of parameter uncertainty
on the study ﬁndings, particularly with respect to treatment
efﬁcacy and the costs of prophylaxis and treating an IFI. The
parameters and distributions of the variables included in
the probabilistic analysis are summarized in Table 2. A random
number generator was used to “draw” parameter values from
each distribution, which was then run through the model. This
process of drawing parameters and running the model was
repeated 1000 times, which is equivalent to 1000 different trials
of posaconazole versus FLU or ITRA. Results of the probabilistic
analysis were depicted graphically as a joint distribution of incre-
mental costs and life-years. These analyses were conducted for
the cost per life-year-saved outcome only, due to the challenges
involved with interpreting a threshold ratio for cost per IFI
avoided.
Results
Base-Case Findings
Results from the clinical trial of posaconazole versus FLU or
ITRA for the prevention of IFIs among neutropenic patients with
AML and MDS indicated that posaconazole is associated with
fewer IFIs per patient (0.05 vs. 0.11) relative to FLU or ITRA.
Base-case results from the economic model suggest that use of
posaconazole yields an additional 0.08 undiscounted life-years
per patient (2.70 vs. 2.62) and 0.07 discounted life-years (2.50
vs. 2.43) over a lifetime horizon. Prophylaxis with posaconazole
also saves about $600 in discounted medical care costs (Table 3).
Although the average cost of prophylaxis was higher in the
posaconazole group ($2081 vs. $63), this difference was offset
by lower costs associated with treating IFIs ($1850 vs. $4443)
(Fig. 2). As posaconazole is more effective and less costly relative
to FLU or ITRA, it is said to be “dominant” from a cost-effective
point of view [17].
Alternative Scenario
In the base-case analysis, the risk of death due to IFI was assumed
to be equal between groups (i.e., independent of prophylaxis
regimen). In an alternative analysis, we employed prophylaxis-
speciﬁc case fatality rates observed in the trial. Under this
scenario, posaconazole is associated with 0.09 additional dis-
counted life-years (2.51 vs. 2.42) relative to FLU or ITRA, and
therefore remains dominant.
One-Way Sensitivity Analyses
Results from one-way sensitivity analyses suggest that model
results are robust to changes in the risk of IFI with FLU or ITRA,
the cost of treating an IFI, the duration of prophylaxis, and the
Table 2 Distributions and parameters used in the probabilistic sensitivity analysis
Variable Distribution Parameters Data source
Probability of IFI
Fluconazole or itraconazole Beta a = 33, b = 265 [10]
Posaconazole Beta a = 14, b = 290 [10]
Probability of IFI-related death, given IFI
Fluconazole or itraconazole Beta a = 21, b = 26 [10]
Posaconazole Beta a = 21, b = 26 [10]
Probability of other death within 100 days Beta a = 95, b = 507 [10]
Mean exposure with prophylaxis (days)
Posaconazole Gamma Mean = 28.9, SE = 1.20 [10]
Fluconazole or itraconazole Gamma Mean = 24.9, SE = 0.98 [10]
IFI treatment costs* Gamma Mean = $40,583, SE = $3080 Unpublished data from HCUP-NIS analysis,
Schering-Plough Corp., 2007
*Mean and SE updated to 2006 US$.
IFI, invasive fungal infection; HCUP-NIS, Healthcare Cost and Utilization Project-Nationwide Inpatient Sample; SE, standard error.
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5-year relative survival for AML (Table 4). When the risk of IFI
with posaconazole is varied from its low to high value, the
incremental cost-effectiveness ratio for posaconazole versus FLU
or ITRA ranges from cost saving to $48,600 per life-year saved.
The corresponding range for the incremental cost per IFI avoided
is from cost saving to $52,400 per IFI avoided.
Probabilistic Sensitivity Analyses
Probabilistic sensitivity analyses were performed by simulta-
neously varying the risks of IFI, IFI-related death, other death
within 100 days, themean duration of prophylaxis, and the cost of
treating an IFI. A plot of the incremental costs versus incremental
life-years for 1000 simulations is shown in Figure 3. The majority
of the points lies in the region below the horizontal axis and to the
right of the vertical axis, where posaconazole is both more effec-
tive and less costly than FLU or ITRA (i.e., dominant). Results
from the probabilistic sensitivity analysis indicate that posacona-
zole has a 73% probability of being dominant (i.e., less costly,
more effective) versus FLU or ITRA, and a 96% probability of
being cost-effective at a $50,000 per life-year saved threshold.
Discussion
Results from this analysis suggest that the use of posaconazole
for the prevention of IFIs among AML and MDS patients with
chemotherapy-induced neutropenia is cost saving compared to
FLU or ITRA. In the trial-based analyses, posaconazole was
associated with 0.06 fewer IFIs per patient relative to FLU or
ITRA. Results from the cost-effectiveness analysis suggest that
prophylaxis with posaconazole saves $600 and 0.07 additional
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Figure 2 Costs per patient receiving prophylaxis
for invasive fungal infections (IFIs) with posacona-
zole versus ﬂuconazole or itraconazole among
high-risk neutropenic patients in the United States.
Table 3 Cost-effectiveness of posaconazole versus ﬂuconazole or itraconazole in the prevention of IFIs among high-risk neutropenic patients in the
United States*
Prophylaxis strategy Total costs
Incremental
cost IFI events IFIs avoided Life-years
Life-years
saved (LYS)
ICER (Cost per
IFI avoided)
ICER (Cost
per LYS)
Posaconazole $3900 — 0.05 — 2.50 — — —
Fluconazole or
itraconazole
$4500 $600 0.11 -0.06 2.43 -0.07 Dominated Dominated
*Results are presented per patient treated with prophylaxis.Total costs include those for antifungal prophylaxis and treatment for IFIs among those who experience them.
ICER, incremental cost-effectiveness ratio; IFI, invasive fungal infection; LYS, life-years saved.
Table 4 One-way sensitivity analyses of the cost-effectiveness of posaconazole versus ﬂuconzaole or itraconazole among high-risk neutropenic patients
in the United States
Parameter Basecase Low value High value ICER for low value ($/LYS) ICER for high value ($/LYS)
Risk of IFI on posaconazole* 0.05 0.0024 0.0883 Cost saving $48,600
Risk of IFI on ﬂuconazole or itraconazole† 0.11 0.0825 0.1375 $1200 Cost saving
IFI treatment costs‡ $40,583 $37,503 $43,663 Cost saving Cost saving
Mean exposure with prophylaxis (days)§
Posaconazole 28.9 7.8 50.0 Cost saving $13,500
Fluconazole or itraconazole 24.9 7.7 42.1 Cost saving Cost saving
5-year relative survival with AML† 0.21 0.1575 0.2625 Cost saving Cost saving
*Range estimated using the 95% conﬁdence interval for the difference in risk between the posaconazole and ﬂuconazole or itraconazole arms from the trial.
†Ranges estimated as 25% of model values.
‡Range estimated using the standard error of the mean difference between IFI cases and controls from the HCUP database analysis.
§Ranges estimated using the SD of the mean exposures from the trial.
AML, acute myelogenous leukemia; ICER, incremental cost-effectiveness ratio; IFI, invasive fungal infection; LYS, life-year saved.
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discounted life-years per patient (0.08 undiscounted life-years)
relative to FLU or ITRA. In one-way sensitivity analyses,
the incremental cost-effectiveness ratio was most sensitive to
changes in the risk of IFI on posaconazole, ranging from cost
saving to $48,600 per life-year saved when the risk of IFI on
posaconazole was varied across its low and high values, respec-
tively. Results from the probabilistic sensitivity analysis indi-
cated that posaconazole has a 73% probability of being cost
saving.
Several other economic studies of antifungal use for the treat-
ment or prevention of IFIs exist in the literature [2,3,18–22], but
we identiﬁed only three that estimated the incremental cost-
effectiveness of antifungal prophylaxis strategies for patients at
high-risk for IFI [21,22]. Scharfstein et al. (1997) estimated the
incremental cost-effectiveness of prophylaxis with FLU versus no
prophylaxis among patients with AIDS; among patients with
CD4 counts below 200 cells/mm3, FLU had an incremental
cost-effectiveness ratio of $240,000 per life-year saved relative
to no prophylaxis [21]. In a population comparable to that of
the Cornely et al. (2007) trial, Nomura et al. (2006) conducted
a cost-effectiveness analysis of three treatment strategies for
IFIs: prophylaxis with FLU, empirical strategy with intravenous
amphotericin B, and no prophylaxis (intravenous micafungin
at IFI diagnosis) among neutropenic patients with AML. They
reported incremental cost-effectiveness ratios of $625 and $652
per life-year saved for FLU relative to the no prophylaxis
and prophylaxis with empirical amphotericin B strategies,
respectively [22]. Most recently, de Vries and colleagues (2008)
estimated the cost-effectiveness of ITRA versus FLU and no
prophylaxis for the prevention of IFIs among patients with hema-
tological malignancies [23]. They concluded that ITRA may be
cost saving versus FLU in speciﬁc subgroups of patients. Note
that de Vries et al. employed data from a meta-analysis (not
a randomized controlled trial), did not indicate the assumed
duration of prophylaxis (which is a signiﬁcant cost driver), and
estimated total costs and IFIs over a 1-year period only (without
accounting for death). As this patient population is at high risk of
death due to both the underlying disease as well as IFI, a lifetime
model horizon is warranted.
As prophylaxis is now a recommended treatment strategy
among high-risk patients [7], a “no prophylaxis” strategy is no
longer an appropriate comparison for an economic evaluation. In
comparing two active prophylaxis strategies over a lifetime
horizon, we found that the use of posaconazole for the preven-
tion of IFIs among neutropenic AML and MDS patients is cost
saving compared to a strategy of FLU or ITRA, despite the fact
that the acquisition cost of posaconazole is considerably higher
than either of the alternatives. This is due to the fact that posa-
conazole prevents more IFIs than the comparator; the difference
in the incidence of IFI is so great that the additional cost of
prophylaxis for patients receiving posaconazole ($2000 per
patient) is more than offset by the decreased costs of the treat-
ment of IFIs ($2600 lower per patient).
Some limitations of our analysis should be noted. For one,
the clinical trial data on which we based our analysis had a
maximum follow-up of 100 days. Thus, we extrapolated the
model to a lifetime time horizon using long-term mortality data
from the literature and 1-month Markov cycles that were run
until all patients have died. In the absence of data to the contrary,
we assumed that long-term survival is independent of having an
IFI; that is, risk of death after 100 days is assumed to be equal for
those who did and did not develop an IFI. Additionally, we
employed equal rates of IFI-related death for both prophylaxis
groups. Although the Kaplan–Meier analysis of time to death
from any cause as well as the difference in death rates from IFI
both indicated a signiﬁcant survival beneﬁt for posaconazole
(P = 0.04 and P = 0.01, respectively), our model required esti-
mates of case fatality for IFI; that is, IFI-related death conditional
on having an IFI. It is unknown if the observed (albeit, not
statistically signiﬁcant) difference in case fatality rates is due to
the fact that posaconazole prevents more severe infections asso-
ciated with higher death rates, or whether the signiﬁcant differ-
ence in IFI-related death observed in the trial was driven by the
difference in IFI incidence rates. Nevertheless, we conservatively
assumed that the case fatality rates were the same for both
groups, and conducted an alternative analysis in which we
employed the treatment-speciﬁc rates observed in the trial.
Results indicated that posaconazole would be cost saving under
either scenario.
Ideally, costs of care for AML patients would be included in
the cost-effectiveness analysis, with the relevant measure being
the incremental cost associated with treating AML among those
who live longer as a result of not developing a fatal IFI. That is,
the ideal cost measure would exclude initial and terminal costs of
treating AML. Costs of AML are scarce in the literature; further-
more, studies that exist are outdated and do not include current
treatment patterns [24]. One of the only studies on the costs of
AML in the US setting was a retrospective analysis of data from
the SEER-Medicare database [14]. Authors of this study reported
survival, health-care utilization, and Medicare payments for
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elderly patients with an initial AML diagnosis between 1991 and
1996. The average age in this study was 77 years, which is quite
a bit older than our cohort (starting age, 50 years); furthermore,
median survival among the study population was only 2 months.
Authors of this study reported that most of the total costs among
these patients were incurred in the ﬁrst few months; as they did
not live much beyond a few months, it may be assumed that most
of the costs for these patients were incurred around diagnosis and
death. This conclusion is consistent with results from a more
recent study of patients with cancer of various sites; authors of
this paper reported that mean costs of care were highest in the
initial and last phases of life for patients with all tumor types
[15]. Given this, we excluded costs of AML under the premise
that the incremental costs during the continuing phase of treat-
ment is relatively low, and would not signiﬁcantly affect the
cost-effectiveness results. That said, we conducted threshold
analyses in which we calculated the monthly costs of AML that,
if included in the cost-effectiveness analysis, would yield various
incremental cost-effectiveness ratios. Our threshold analyses
indicate that if the average monthly cost of AML (excluding
initial and terminal costs) is $700, costs for the two prophylaxis
strategies would be equal. If the average monthly cost of AML is
$5000, the incremental cost-effectiveness ratio for posaconazole
versus FLU or ITRA would be $50,000 per life-year saved, and
if the monthly cost of AML is $10,000, the incremental cost-
effectiveness ratio for posaconazole would be $100,000 per life-
year saved.
The clinical trial on which the model is based compared
prophylaxis with posaconazole versus FLU or ITRA. In this
multinational trial, investigators were instructed to select either
FLU or ITRA at the start of the study (for use throughout the
study) based on local treatment patterns [10]. Although it may be
desirable to compare posaconazole to FLU and ITRA separately
(in part because ITRA has a wider spectrum of activity than
FLU, including activity against aspergillus [10]), the trial was not
powered to detect differences between posaconazole and the two
azoles separately. In fact, the sample size for ITRA (N = 58) was
small relative to FLU (N = 240). Trial investigators compared the
rates of IFI between the two groups, and reported that the rates
of proven or probable IFI were similar (8% in the FLU group vs.
10% in the ITRA group). In addition, and somewhat surpris-
ingly, the rate of invasive aspergillosis was higher in the ITRA
group relative to FLU (9% vs. 6%, respectively); the difference
was not statistically signiﬁcantly different. In light of these facts,
and consistent with the clinical trial, we pooled data for the FLU
and ITRA groups.
A common outcome measure in cost-effectiveness analysis is
quality-adjusted life-years (QALYs). QALYs allow for the quality
and length of life to be captured in a single metric by assigning
a utility weight (representing quality of life) to each period of
time and summing across all periods [16]. Although QALYs are
a preferred metric in cost-effectiveness analyses [16], we are
unaware of any published utility weights for AML or IFI in the
literature, and therefore could not include them in the base-case
analysis. To assess the potential impact of quality of life on the
model results, we conducted an analysis in which we applied a
utility weight for AML (the underlying condition) to all life-years
in the model. Results indicated that even if it is assumed that
patients with AML have a utility weight as low as 0.50, posa-
conazole is associated with 0.04 additional QALYs relative to
FLU or ITRA (1.25 vs. 1.21 QALYs respectively), and posacona-
zole remains cost saving. We are not aware of any published
estimates of short-term disutility associated with IFI, but this
disutility would have negligible effects on the incremental cost-
effectiveness ratio. In sum, given that our base-case results indi-
cate that posaconazole is cost saving, inclusion of utility values
would not have altered our conclusions.
Based on clinical evidence, the NCCN recently recommended
that patients with AML and MDS receive prophylaxis with
a mold-active antifungal during periods of neutropenia for the
prevention of IFI [7]. Results of our analysis suggest that pro-
phylaxis with posaconazole is very likely to be a cost-effective
alternative to FLU or ITRA in the prevention of IFIs among
neutropenic AML and MDS patients, and may result in cost
savings.
Source of ﬁnancial support: Schering-Plough Corp., Kenilworth, NJ, USA.
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